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Background: To estimate the potential cost savings by following the current Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) guideline recommendations in patients 
being treated for chronic obstructive pulmonary disease (COPD) with the combination 
of long-acting β2-agonist (LABA), long-acting muscarinic antagonist (LAMA) or inhaled 
corticosteroids (ICS).
Methods: The Geisinger Health System (GHS) database was utilized to identify subjects 
between January 1, 2004 to March 12, 2007. The index date was based on the first prescription 
of a LAMA plus LABA, LAMA plus LABA/ICS, or LABA plus ICS. Patients were included in 
the study if they: had a COPD diagnosis; had data representative of treatment 12 months prior to 
and 12 months post index date; were 40 years of age or over; had no prior diagnosis for asthma; 
and had pulmonary function test (PFT) data. We examined the baseline characteristics of these 
patients along with their healthcare resource utilization. Based on PFT data within 30 days of 
the index date, a subgroup was classified as adhering or non-adhering to GOLD guidelines.
Results: A total of 364 subjects could be classified as adhering or non-adherent to current 
GOLD guidelines based on their PFT results. The adherent subgroup received COPD medica-
tions consistent with current GOLD guidelines. Of the LAMA plus LABA cohort, 25 patients 
adhered and 39 patients were non-adherent to current GOLD guidelines. In the cohort of LABA 
plus ICS, 74 patients were adherent and 180 patients non-adherent to current GOLD guidelines. 
In the cohort of LAMA plus LABA/ICS, 21 patients were adherent and 25 patients non-adherent 
to current GOLD guidelines. GOLD adherence was associated with mean total cost of all services 
  savings of $5,889 for LAMA plus LABA, $3,330 for LABA + ICS, and $10,217 for LAMA 
plus LABA/ICS cohorts.
Conclusion: Staging of COPD with a PFT and adherence to current GOLD guidelines was 
associated with lower costs in subjects with moderate to severe COPD. Appropriate use of 
LAMA plus LABA, LABA plus ICS, and LAMA plus LABA/ICS has economic as well as 
clinical benefits for patients and payers.
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Introduction
Chronic obstructive pulmonary disease (COPD), characterized by shortness of breath 
and other breathing related problems, is the fourth leading cause of death in the 
United States (US), with more than 120,000 deaths every year.1 Although the National 
Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) 
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reports that 24 million people are affected with COPD, only 
10 million adults were estimated to be diagnosed with COPD 
in 2000.2 The current prevalence rate of COPD is 12 million, 
with an another likely 12 million individuals not knowing that 
they have disease.1 The economic burden (direct and indirect 
costs) of COPD to the US was estimated to be $30.4 billion 
in 2000 which increased to nearly $32.1 billion in 2002.3,4 
In 2002, the direct medical costs constituted $18 billion 
and indirect costs (related to morbidity and mortality) were 
$14.1 billion.3 Prescription drug costs accounted for $2.7 bil-
lion (20.6%) of the total direct COPD costs.
According to the current Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) report, COPD is a 
disease state characterized by airflow limitation that is not 
fully reversible.5 Both small airway disease (obstructive 
bronchiolitis) and parenchymal destruction lead to chronic 
airflow limitations in COPD that varies from individual 
to individual.6 Long-term smoking is the most common 
risk factor associated with COPD and accounts for 80% 
to 90% of the cases.7,8 In addition, a current smoker is 
ten times more likely to die from COPD compared to a 
non-smoker. Other COPD risk factors include heredity, 
second-hand smoke, exposure to air pollution at work and 
in the environment, and a history of childhood respiratory 
infections.9
Spirometry is recommended by the current GOLD 
guidelines to measure airflow limitation as this is the 
most widely available, reproducible test of lung function. 
Spirometry measures an individual’s forced expiratory 
volume in 1 second (FEV1) and forced expiratory vital 
capacity (FVC) based on which COPD is classified into 
four stages of severity.5 The current GOLD guidelines’ 
approach to the management of disease is driven by the 
need to control symptoms. Bronchodilators are central to 
such a therapeutic approach. The main bronchodilators 
are β2-agonists, anticholinergics, theophylline and a 
combination of these medications. The choice among 
these medications depends on individual response, 
availability, and cost. Short-acting inhaled bronchodilators 
are recommended from Stage I onward, on an as-needed 
basis. Long-acting inhaled bronchodilators should be added 
from Stage II onward, on a regular basis, for subjects 
whose symptoms are not controlled with as-needed short-
acting bronchodilators. For stage III to IV , with a history 
of repeated exacerbations, regular treatment with inhaled 
corticosteroids is recommended in addition to long-acting 
bronchodilators.5 Also, the current GOLD guidelines’ 
caution that chronic treatment with oral glucocorticosteroids 
should be avoided.
The lack of association between FEV1 and other elements 
of functional status has increased attention in the multi-
systematic evaluation of COPD to determine severity.5,10
Many subjects with COPD continue to be undiagnosed 
or undertreated, suggesting that the guidelines are not 
being fully utilized.10,11 There is scant empirical evidence 
in the literature that investigates disparity between current 
  guidelines and practice. The objective of this study is to 
estimate the potential cost savings by following current 
GOLD guideline recommendations in patients being treated 
with the combination of long-acting β2-agonist (LABA), 
long-acting muscarinic antagonist (LAMA) or inhaled 
corticosteroids (ICS). The strength of this study is that it 
utilized lung function measured by spirometry to define 
severity.
Methods
Data source
The study utilized data from the Geisinger Health System 
(GHS), which was founded in 1915 and is a physician-led 
organization comprising of 650 plus physicians, 75 medical 
and surgical specialties, and 42 pediatric medical and surgi-
cal subspecialties. GHS, which also has one of the largest 
not-for-profit rural health maintenance organizations in the 
US, has three existing hospitals (primary to quaternary care) 
and 41 community practice offices. The GHS service area 
is limited to the state of Pennsylvania. The core of the data 
originates from an electronic health record (EHR) infrastruc-
ture that contains longitudinal clinical patient data including 
lab results for over 3 million subjects from 1996 to 2008. In 
addition to the electronic health record core, the database 
has Geisinger incurred medical-service cost, charge, and 
payment data dating back to 2003.
Study design and time frame
A retrospective cohort study design was utilized and the 
study duration ranged from January 2004 to December 
2007. The date when the subjects were first prescribed 
COPD therapies of interest – LAMA plus LABA or LABA 
plus ICS, or LAMA plus LABA/ICS – was identified as 
the index date during the study period. Patient data for the 
12 months prior to the index date was evaluated to iden-
tify baseline characteristics. Patient data representative of 
12 months after the index date were examined to compare 
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the healthcare utilization costs of combination therapies, 
LAMA plus LABA to LABA plus ICS, and LAMA plus 
LABA/ICS based on GOLD guidelines.
Study population
Subjects were eligible for this study if they had a diagnosis of 
COPD (identified by International Classification of Diseases, 
Clinical Modification Ninth Revision [ICD9-CM] codes for 
COPD: 491, 492, and 496), did not have an asthma diagno-
sis (ICD-9-CM: 493.0), were at least 40 years of age and 
continuously enrolled for at least 12 months pre- and post-
index date. In observational, retrospective COPD research, 
40 years of age or older is routinely used as an inclusion 
criteria to correctly identify the COPD population and rule-
out miscoding or misdiagnosis of asthma, which is typically 
a younger population. 
In addition, the subjects were required to have a prescrip-
tion for combination therapies, LAMA plus LABA, LABA 
plus ICS, or LAMA plus LABA/ICS. Based on these treat-
ments, subjects were categorized into three mutually exclu-
sive cohorts. The subjects were excluded if their prescribed 
therapy was switched from the index date therapy to another 
within 90 days of start of the therapy. For the subgroup analy-
sis, subjects were also required to have pulmonary function 
test (PFT) data (available from two clinics of GHS).
Identification of demographic and clinical 
characteristics
The demographic characteristics that were identified in 
the study are age, gender, race (white, black, Hispanic), 
smoking history (current, passive, former, never, unknown), 
employment status (employed, unemployed), and insurance 
status (Medicaid, Medicare, commercial, self-pay). The 
clinical characteristics that were assessed are duration of 
COPD prior to index date and through index day, number of 
office visits, emergency room (ER) visits, hospitalizations, 
number of exacerbations defined as sum of length of stay 
during hospitalizations, and number of prescriptions for 
antibiotics and prednisone, concomitant medications 
(related to COPD only and excluding the study drugs) prior 
to index date, mean baseline Deyo–Charlson’s comorbidity 
index (DCI),12 total encounter cost to Geisinger for COPD 
including hospital and physician costs, and PFT data (FEV1% 
predicted and FEV1/FVC% predicted). For LAMA plus 
LABA cohort, subjects were classified as adhering to GOLD 
guideline group, if the medications were prescribed from 
stage II COPD onwards and similarly stage III onwards for 
LABA plus ICS and LAMA plus LABA/ICS cohorts. All the 
costs (encounters) were adjusted to 2006 US dollars based 
on the medical care component of the consumer price index 
(CPI).13 PFT data within 30 days of the index date were used 
to classify subjects into adhering and non-adhering to current 
GOLD guidelines (Table 1) groups.
Statistical analysis
Descriptive statistics were utilized to depict the study 
population characteristics at baseline. To determine if there 
were any differences in baseline characteristics (both demo-
graphic and clinical) among the three drug therapy cohorts, 
Chi-square tests for categorical variables, and t-tests for 
continuous variables (Wilcoxon-Mann-Whitney test was used 
if n , 30) were utilized. The total cost for adhering and non-
adhering groups were compared by using t-test at baseline 
and follow-up. All results were measured at the 5% significant 
level (P # 0.05) and SAS version 9.1 (SAS Institution Inc, 
Cary, NC) was used for the analyses.
Results
A total of 30,024 subjects initially received one of the study 
drug combinations between 2004 and 2007 and of this group 
Table 1 gOLD treatment guidelines
Severity level Recommended therapy
Stage I (mild) 
(FEV1/FVC , 70% and FEV1 $ 80% predicted)
Short-acting inhaled bronchodilator as needed and if not available, a regular  
treatment with slow-release theophylline serves as an alternative treatment.
Stage II (moderate) 
(FEV1/FVC , 70% and FEV1 predicted between 80% and 50%)
One or more long-acting bronchodilators as needed and rehabilitation  
to reduce symptoms improve quality of life and increase physical  
and emotional participation in everyday functions.
Stage III (severe) 
(FEV1/FVC , 70% and FEV1 predicted between 50% and 30%)
Regular treatment with inhaled glucocorticosteroids if repeated  
exacerbations in addition to regular bronchodilators.
Stage IV (very severe) 
(FEV1/FVC , 70% and FEV1 , 30%)
Long-term chronic oxygen therapy if respiratory failure and surgical  
treatment should be considered.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced expiratory capacity.
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70% (n = 20,923) were $40 years old. After applying the 
other inclusion criteria, 68 subjects were identified in LAMA 
plus LABA cohort, 387 in LABA plus ICS, and 57 in LAMA 
plus LABA/ICS cohorts. A total of 364 subjects had PFT data 
permitting assessment of compliance with GOLD guidelines 
based on their stage of COPD (Figure 1).
Baseline characteristics  
(demographic and clinical)
A summary of baseline characteristics is provided in Table 2. 
The mean age of subjects ranged from 66 to 68 years across 
all the cohorts of the study. The proportion of males (range: 
60%–71%) was higher than females (range: 29%–40%) 
across the study cohorts with predominant race (99%) 
being white. The majority of study subjects were former 
smokers (64%), and unemployed (88%) with a commercial 
insurance (60%).
A greater number of subjects (51%) in all the treatment 
cohorts had chronic airway obstruction, not otherwise 
specified as a COPD diagnosis as opposed to chronic 
bronchitis and emphysema. The mean DCI ranged from 
3.06 to 3.82 and mean number of concomitant medications 
n = 30,024
Patients first prescribed with LAMA +
LABA or LABA + ICS or LAMA +
LABA/ICS
n = 20,923
Age ≥ 40 years
n = 12,381
Patients who are continuously eligible
for 12 months pre- and post-index date
n = 4,879
Patients with COPD diagnosis by the
presence of ICD-9 prior and on index
date 
n = 3,567
Excluding patients with asthma diagnosis
prior and on index date
n = 761
Patients with PFT data 12 months pre-
and post-index date
n = 64
PFT within 30 days
of index date
n = 46
PFT within 30 days
of index date
n = 254
PFT within 30 days
of index date
n = 387
No switching within
90 days
n = 68
No switching within
90 days
n = 57
No switching within
90 days
n = 113
LAMA + LABA
n = 510
LABA + ICS
n = 138
LAMA + LABA + ICS
Figure 1 Population identification.
Abbreviations: LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroids; COPD, chronic obstructive pulmonary disease; PFT, 
pulmonary function test.
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ranged from 8.18 to 16 across the cohorts. The duration 
of COPD prior to index date ranged from 139 to 203 days 
among the cohorts of the study (Table 2). The mean DCI 
ranged from 3.06–3.82 for the three cohorts with a signifi-
cant difference between LAMA + LABA and LABA/ICS 
cohorts. The mean number of concomitant medications 
ranged from 8.18–16 across the cohorts with a significant 
difference between LAMA + LABA and LAMA + LABA/
ICS cohorts. The duration of COPD prior to index date 
ranged from 139–203 days among the cohorts of the study 
with a significant difference between LAMA + LABA and 
LABA/ICS cohorts.
Subjects prescribed LAMA plus LABA differed sig-
nificantly (P , 0.05) by race, smoking history, COPD 
diagnosis, mean DCI and duration of COPD prior to index 
date compared to LABA plus ICS. There was a statisti-
cally significant difference (P , 0.05) observed in only 
mean number of concomitant medications for LAMA plus 
LABA cohort when compared with LAMA plus LABA/ICS. 
A summary of baseline health care utilization and total 
Geisinger encounter costs (in 2006 US dollars) are pre-
sented in Table 3. In the pre-index date period (baseline), 
subjects prescribed LAMA plus LABA differed signifi-
cantly (P , 0.05) in mean number of outpatient   visits (5 vs 
Table 2 Overall patient characteristics at baseline
Characteristics LAMA plus LABA  
N/mean (% or SD)
LABA plus inhaled corticosteroids 
N/mean (% or SD)
LAMA plus LABA/ICS 
N/mean (% or SD)
N 68 387 57
Age 66.46 (9.67) 66.08 (10.88) 67.74 (10.57)
gender
  Males 48 (70.59%) 233 (60%) 39 (68.42%)
  Females 20 (29.41%) 154 (40%) 18 (31.58%)
Race
  White 66 (97.06%) 385 (99.5%) 57 (100%)
  Black 2 (2.94%) – –
  Hispanic – 2 (0.52%) –
Employment
  Employed 9 (13.24%) 44 (11.37%) 6 (10.53%)
  Unemployed 58 (85.29%) 343 (89%) 51 (89.47%)
  Unknown 1 (1.47%) 27 (1.17%) –
Insurance status
  Medicaid 1 (1.47%) 19 (4.91%) 2 (3.51%)
  Medicare 25 (36.76%) 135 (35%) 15 (26.32%)
  Commercial 42 (61.76%) 224 (58%) 39 (68.42%)
  Self-pay – 7 (1.81%) 1 (1.75%)
  VA – 1 (0.26%) –
  Unknown – 1 (0.26%) –
Smoking history
  Current smoker 13 (22.81%) 92 (23.77%) 10 (17.54%)
  Passive smoker 1 (1.75%) 1 (0.26%) –
  Former smoker 42 (73.68%) 245 (63.31%) 41 (71.93%)
  Never smoker 4 (7.02%) 33 (8.53%) 2 (3.51%)
  Unknown 8 (14.04%) 14 (3.62%) 4 (7.02%)
COPD diagnosis
  Chronic bronchitis 4 (5.88%) 43 (11.11%) 3 (5.26%)
  Emphysema 31 (45.59%) 94 (24.29%) 16 (28.07%)
    Chronic airway obstruction,  
not otherwise
24 (35.29%) 209 (54.01%) 27 (47.37%)
  Any combinations 9 (13.24%) 39 (10.08%) 11 (19.3%)
Mean DCI 3.74 (2.45) 3.06 (2.07)* 3.82 (2.34)
Mean number of concomitant  
medications
9.53 (12.85) 8.18 (17.62) 16 (18.59)*
Duration of COPD prior  
to index date
189 (153) 139 (150)* 203 (161)
Note: If the diagnosis of COPD is more than 1 year, the duration of COPD prior to index date is set to 365 days. Charlson’s comorbidity index; *significant at ,0.05 level 
compared to LABA + LAMA cohort.
Abbreviations: COPD, chronic obstructive pulmonary disease; DCI, Deyo–Charlson’s comorbidity index; LAMA, long-acting muscarinic antagonist; LABA, long-acting 
β2-agonist; ICS, inhaled corticosteroids; CCI, Charlson Comorbidity Index; SD, standard deviation.
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3.5 or 8.3), oxygen use (62% vs 24% or 37%) as compared 
to LABA plus ICS or LAMA plus LABA/ICS groups 
respectively. Compared to subjects with LAMA plus LABA, 
the mean number of office visits (2.8 vs 2.4 or 4.7) and mean 
number of hospitalizations (2.1 vs 1.9 or 3.1) were found 
to be significantly different (P , 0.05) in only LAMA plus 
LABA/ICS group. There were no statistically significantly 
differences identified in mean hospital costs ($5,661 vs 
$4,701 or $10,553), mean physician costs ($1,371 vs $995 
or $2,110), and total encounter costs to Geisinger ($6,948 
vs $4,538 or $12,077).
The baseline predicted values of FEV1%, FEV1/FVC%, 
and FVC% ranged from 41.9 to 55.41, 70.44 to 78.46, and 
61.44 to 73.51 respectively with statistically significant dif-
ferences (P , 0.05) in FEV1% and FVC% predicted values in 
LAMA plus LABA/ICS cohort as compared to LAMA plus 
LABA cohort. Also, significant differences were determined 
in mean change of FVC% predicted values between baseline 
and follow-up periods in LABA plus ICS and LAMA plus 
LABA/ICS cohorts. The mean change of FEV1% predicted 
values was found to be significantly different (P , 0.05) 
in only LAMA plus LABA/ICS cohort (Table 4). This is 
noteworthy as anything greater than 5% in terms of predicted 
values is regarded as being clinically significant.
Of the overall cohort, 364 subjects had PFT data within 
30 days of the index date and thus could be classified as 
adhering or not adhering to current GOLD guidelines. Of 
68 patients in the LAMA plus LABA cohort, 25 patients 
adhered and 39 patients were non-adherent to current GOLD 
guidelines. There are 387 patients in the cohort of LABA plus 
ICS with 74 patients adhering and 180 patients non-adherent 
to current GOLD guidelines. There are 57 patients in the 
cohort of LAMA plus LABA/ICS with 21 patients adhering 
and 25 patients non-adherent to current GOLD guidelines. 
Overall, 33% of the 364 subjects received medication therapy 
consistent with current GOLD guidelines. The mean cost 
savings associated with adherence to GOLD guidelines were: 
$5,889 for LAMA plus LABA cohort, $3,330 for LABA plus 
ICS cohort, and $10,217 for LAMA + LABA/ICS cohort 
respectively (Table 5).
Discussion
According to current GOLD guidelines, COPD medications 
if prescribed according to the stages of severity will prevent 
disease progression, relieve symptoms, improve health status, 
prevent exacerbations, and eventually reduce mortality. The 
classification of subjects according to their pulmonary func-
tion data as outlined in current GOLD guidelines has been 
depicted as an independent predictor for exacerbation-related 
hospitalizations, which implies that the severe subjects 
(Stage IV) tend to have more hospitalizations as a result of 
an exacerbation.14 In addition, it has been established that 
Table 3 Health care utilization and total geisinger encounter costs for overall COPD subjects at baseline
Outcomes LAMA plus LABA  
(n = 68)  
N/mean (% or SD)
LABA plus ICS  
(n = 387)  
N/mean (% or SD)
LAMA plus LABA/ICS   
(n = 57)  
N/mean (% or SD)
Inpatient
  Number of admissions 2.1 (1.5) 1.9 (1.2) 3.1 (2.1)
  Number of days in hospital 17.8 (45.1) 8.9 (11.6) 14.8 (13.3)
Emergency room visit
  Number of admissions 2 (1) 1.1 (0.3) 1.5 (0.7)
Outpatient
  Number of outpatient visits 5 (3.9) 3.5 (3.2) 8.3 (8.7)
  Number of office visits 2.8 (2.2) 2.4 (2) 4.7 (4.1)
Oxygen use 42 (61.76) 91 (23.51) 21 (36.84)
Hospital costs 5,661.3 (10,937.6) 4,701.7 (15,910) 10,553.3 (24,066.2)
Procedure costs 824.8 (674.4) 492 (468.9) 1065.9 (861)
Drug administering costs 750.6 (2,791.8) 40 (81) 1.9 (2.2)
Physician costs 1,371.3 (2,480.5) 995.2 (3,167) 2,109.9 (3,693.3)
Number of prescriptions for antibiotics  
and prednisone
4.4 (4) 3.3 (3) 6.1 (5.4)
Drug administering costs related to  
antibacterials and prednisone
20.5 (19.9) 19.2 (34.5) 35.4 (37.9)
Mean number of exacerbations 7.76 (8.69) 6.06 (9.07) 12.92 (14.72)
Total encounter costs to geisinger 6,948.08 (13,084.5) 4,538.3 (16,976.84) 12,076.89 (27,032.88)
Note: Outpatient hospital cost, procedure cost and medication cost are not calculated if they are included in inpatient hospital cost. 
Abbreviations: LAMA, long-acting muscarinic antagonist; LABA, long-acting β2-agonist; ICS, inhaled corticosteroids; hospital costs include inpatient hospital costs and 
outpatient hospital costs; SD, standard deviation. 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
206
Asche et alInternational Journal of COPD 2012:7
T
a
b
l
e
 
4
 
P
F
T
 
v
a
l
u
e
s
 
o
f
 
t
h
e
 
s
t
u
d
y
 
p
o
p
u
l
a
t
i
o
n
 
a
t
 
b
a
s
e
l
i
n
e
 
a
n
d
 
m
e
a
n
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
a
t
 
f
o
l
l
o
w
-
u
p
P
F
T
 
v
a
l
u
e
L
A
M
A
 
p
l
u
s
 
L
A
B
A
 
(
n
 
=
 
6
8
)
L
A
B
A
 
p
l
u
s
 
i
n
h
a
l
e
d
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
 
 
(
n
 
=
 
3
8
7
)
L
A
M
A
 
p
l
u
s
 
L
A
B
A
/
I
C
S
 
(
n
 
=
 
5
7
)
T
i
o
t
r
o
p
i
u
m
 
p
l
u
s
 
L
A
B
A
 
v
s
 
 
L
A
B
A
 
p
l
u
s
 
I
C
S
T
i
o
t
r
o
p
i
u
m
 
p
l
u
s
 
L
A
B
A
 
v
s
 
 
t
i
o
t
r
o
p
i
u
m
 
p
l
u
s
 
L
A
B
A
/
I
C
S
M
e
a
n
 
(
S
D
)
 
 
a
t
 
b
a
s
e
l
i
n
e
M
e
a
n
 
c
h
a
n
g
e
 
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
S
D
)
M
e
a
n
 
(
S
D
)
 
 
a
t
 
b
a
s
e
l
i
n
e
M
e
a
n
 
c
h
a
n
g
e
 
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
S
D
)
M
e
a
n
 
(
S
D
)
 
 
a
t
 
b
a
s
e
l
i
n
e
M
e
a
n
 
c
h
a
n
g
e
 
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
S
D
)
P
-
v
a
l
u
e
P
-
v
a
l
u
e
F
E
V
1
1
.
4
7
 
(
0
.
6
1
)
0
.
0
4
 
(
0
.
2
1
)
1
.
5
1
 
(
0
.
7
0
)
0
.
0
2
 
(
0
.
1
7
)
1
.
4
2
 
(
0
.
6
3
)
0
.
0
1
 
(
0
.
1
8
)
0
.
0
4
0
0
*
0
.
4
1
6
0
F
E
V
1
/
F
V
C
5
0
.
3
5
 
(
1
5
.
4
2
)
1
.
6
3
 
(
5
.
4
1
)
*
5
7
.
9
4
 
(
1
7
.
8
1
)
0
.
1
4
 
(
4
.
2
4
)
5
4
.
3
8
 
(
1
2
.
5
7
)
–
0
.
6
4
 
(
2
.
6
0
)
0
.
0
5
6
2
0
.
0
0
5
7
*
F
V
C
2
.
9
2
 
(
0
.
9
5
)
0
.
0
0
 
(
0
.
3
5
)
2
.
5
8
 
(
0
.
8
7
)
–
0
.
0
3
 
(
0
.
3
6
)
2
.
6
0
 
(
0
.
9
1
)
0
.
0
2
 
(
0
.
2
7
)
0
.
5
9
6
9
0
.
6
9
6
4
N
o
t
e
:
 
t
-
t
e
s
t
 
f
o
r
 
c
o
n
t
i
n
u
o
u
s
 
v
a
r
i
a
b
l
e
s
 
(
*
s
i
g
n
i
fi
c
a
n
t
 
a
t
 
,
0
.
0
5
 
l
e
v
e
l
)
.
 
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
L
A
M
A
,
 
l
o
n
g
-
a
c
t
i
n
g
 
m
u
s
c
a
r
i
n
i
c
 
a
n
t
a
g
o
n
i
s
t
;
 
L
A
B
A
,
 
l
o
n
g
-
a
c
t
i
n
g
 
β
2
-
a
g
o
n
i
s
t
;
 
I
C
S
,
 
i
n
h
a
l
e
d
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
;
 
F
E
V
1
,
 
f
o
r
c
e
d
 
e
x
p
i
r
a
t
o
r
y
 
v
o
l
u
m
e
 
i
n
 
1
 
s
e
c
o
n
d
;
 
F
V
C
,
 
f
o
r
c
e
d
 
v
i
t
a
l
 
c
a
p
a
c
i
t
y
;
 
P
F
T
,
 
p
u
l
m
o
n
a
r
y
 
f
u
n
c
t
i
o
n
 
t
e
s
t
;
 
S
D
,
 
s
t
a
n
d
a
r
d
 
d
e
v
i
a
t
i
o
n
.
T
a
b
l
e
 
5
 
T
o
t
a
l
 
c
o
s
t
 
s
a
v
i
n
g
s
 
o
f
 
a
d
h
e
r
i
n
g
 
t
o
 
t
h
e
 
g
O
L
D
 
g
u
i
d
e
l
i
n
e
s
V
a
r
i
a
b
l
e
s
L
A
M
A
 
p
l
u
s
 
L
A
B
A
 
M
e
a
n
 
(
S
D
)
L
A
B
A
/
I
C
S
 
M
e
a
n
 
(
S
D
)
L
A
M
A
 
p
l
u
s
 
L
A
B
A
/
I
C
S
 
M
e
a
n
 
(
S
D
)
A
d
h
e
r
i
n
g
N
o
n
-
a
d
h
e
r
i
n
g
A
d
h
e
r
i
n
g
N
o
n
-
a
d
h
e
r
i
n
g
A
d
h
e
r
i
n
g
N
o
n
-
a
d
h
e
r
i
n
g
N
u
m
b
e
r
 
o
f
 
s
u
b
j
e
c
t
s
2
5
3
9
7
4
1
8
0
2
1
2
5
T
o
t
a
l
 
e
n
c
o
u
n
t
e
r
 
c
o
s
t
s
 
a
t
 
b
a
s
e
l
i
n
e
9
,
1
9
2
 
(
1
7
,
1
3
2
)
5
,
9
4
0
 
(
1
0
,
2
5
2
)
5
,
8
4
0
 
(
2
8
,
7
2
2
)
5
,
0
3
2
 
(
1
4
,
8
9
1
)
8
,
6
4
2
 
(
1
6
,
6
2
1
)
1
6
,
6
2
8
 
(
3
6
,
7
1
0
)
T
o
t
a
l
 
e
n
c
o
u
n
t
e
r
 
c
o
s
t
s
 
a
t
 
f
o
l
l
o
w
-
u
p
8
,
9
6
0
 
(
1
3
,
2
6
8
)
1
2
,
2
0
4
 
(
2
1
,
3
4
0
)
9
,
4
8
5
 
(
1
6
,
6
6
3
)
1
3
,
6
1
2
 
(
2
6
,
1
3
9
)
9
,
5
2
3
 
(
1
4
,
9
7
6
)
2
8
,
1
8
9
 
(
3
8
,
3
4
2
)
C
h
a
n
g
e
 
i
n
 
t
o
t
a
l
 
e
n
c
o
u
n
t
e
r
 
c
o
s
t
 
b
e
t
w
e
e
n
 
 
f
o
l
l
o
w
-
u
p
 
a
n
d
 
b
a
s
e
l
i
n
e
–
1
,
3
0
7
 
(
2
0
,
0
9
0
)
4
,
5
8
2
 
(
1
7
,
3
0
2
)
3
,
4
9
7
 
(
3
2
,
7
6
6
)
6
,
8
2
7
 
(
2
6
,
6
1
4
)
8
8
1
 
(
1
9
,
5
3
2
)
1
1
,
0
9
8
 
(
5
1
,
6
4
7
)
T
o
t
a
l
 
c
o
s
t
 
s
a
v
i
n
g
s
 
o
f
 
a
d
h
e
r
i
n
g
 
t
o
 
g
O
L
D
 
g
u
i
d
e
l
i
n
e
s
$
5
,
8
8
9
$
3
,
3
3
0
$
1
0
,
2
1
7
N
o
t
e
s
:
 
T
o
t
a
l
 
c
o
s
t
 
s
a
v
i
n
g
s
 
o
f
 
a
d
h
e
r
i
n
g
 
t
o
 
c
u
r
r
e
n
t
 
g
O
L
D
 
g
u
i
d
e
l
i
n
e
s
 
=
 
(
c
h
a
n
g
e
 
i
n
 
t
o
t
a
l
 
c
o
s
t
 
f
o
r
 
s
u
b
j
e
c
t
s
 
a
d
h
e
r
i
n
g
 
t
o
 
c
u
r
r
e
n
t
 
G
O
L
D
 
g
u
i
d
e
l
i
n
e
s
 
–
 
c
h
a
n
g
e
 
i
n
 
t
o
t
a
l
 
c
o
s
t
 
f
o
r
 
s
u
b
j
e
c
t
s
 
n
o
n
-
a
d
h
e
r
i
n
g
 
t
o
 
c
u
r
r
e
n
t
 
G
O
L
D
 
g
u
i
d
e
l
i
n
e
s
)
.
 
N
o
 
s
i
g
n
i
fi
c
a
n
t
 
d
i
f
f
e
r
e
n
c
e
s
 
w
e
r
e
 
o
b
s
e
r
v
e
d
 
b
e
t
w
e
e
n
 
L
A
M
A
 
p
l
u
s
 
L
A
B
A
 
a
n
d
 
L
A
B
A
 
p
l
u
s
 
I
C
S
 
o
r
 
L
A
M
A
 
p
l
u
s
 
L
A
B
A
/
I
C
S
 
c
o
h
o
r
t
s
 
i
n
 
t
o
t
a
l
 
e
n
c
o
u
n
t
e
r
 
c
o
s
t
s
 
a
t
:
 
b
a
s
e
l
i
n
e
;
 
f
o
l
l
o
w
-
u
p
;
 
a
n
d
 
c
h
a
n
g
e
 
b
e
t
w
e
e
n
 
f
o
l
l
o
w
-
u
p
 
a
n
d
 
b
a
s
e
l
i
n
e
 
f
o
l
l
o
w
-
u
p
 
a
n
d
 
b
a
s
e
l
i
n
e
 
(
P
 
.
 
0
.
0
5
)
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
L
A
M
A
,
 
l
o
n
g
-
a
c
t
i
n
g
 
m
u
s
c
a
r
i
n
i
c
 
a
n
t
a
g
o
n
i
s
t
;
 
L
A
B
A
,
 
l
o
n
g
-
a
c
t
i
n
g
 
β
2
-
a
g
o
n
i
s
t
;
 
I
C
S
,
 
i
n
h
a
l
e
d
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
;
 
S
D
,
 
s
t
a
n
d
a
r
d
 
d
e
v
i
a
t
i
o
n
.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
207
Adherence to current guidelines for COPDInternational Journal of COPD 2012:7
failure to use medications in accordance with guidelines 
increases the burden of the disease.15–19 However, there exists 
a gap among primary care physicians and pulmonologists 
in implementing or being consistent with the guidelines for 
diagnosing and treating COPD subjects.20 There is evidence 
that mild to moderate COPD subjects are not being treated 
optimally and that ICS were frequently prescribed by both 
general practitioners and pulmonologists contrary to current 
guideline recommendations.21,22 Furthermore, improved sur-
vival, health status, and lung function with fewer exacerba-
tions were observed with combination therapy as compared to 
monotherapy.23,24 Interestingly, a study found that hospitaliza-
tion leads to improved adherence to GOLD guidelines.25 This 
study is unique in characterizing the cost savings associated 
with adherence to current GOLD guidelines.
Our study found that 66% of subjects with PFT data were 
prescribed medications, inconsistent with their spirometry 
results and current GOLD guideline recommendations. 
Adherence with current GOLD guidelines was associated 
with cost savings in all three cohorts. Subjects prescribed 
LAMA plus LABA/ICS in accordance with current GOLD 
guidelines had the highest mean cost saving of $10,217 
followed by LAMA plus LABA ($5,889) and LABA plus 
ICS ($3,330). These are interesting findings as LAMA plus 
LABA and LABA plus ICS groups are similar at baseline 
except in the case of LABA plus ICS cohort having had 
COPD for approximately 1 year less and as a result they are 
on fewer medications. As such, it is difficult to determine 
if the cost difference we are observing is attributable to the 
baseline differences.
Limitations
The GHS database, like any other electronic medical record 
(EMR) database, may not capture the entire medical history 
of a patient, specifically if the patient is seen by non-network 
providers. In addition, an EMR does not provide any informa-
tion as to whether a service was delivered or a prescription 
was purchased or refilled by the patient. Hence, the study 
assumed that patients adhered perfectly to the prescribed 
therapies of interest. Moreover, an EMR database has miss-
ing data related to out of network healthcare utilizations 
including hospitalizations, ER visits, office visits etcetera, 
and no data were identified for actual drug costs, whereas the 
drug administering costs were present. Thus the true cost of 
treatment may be higher than reported here. Furthermore, a 
relatively small number of subjects that met the other inclu-
sion/exclusion criteria had a record of PFT data.
Conclusion
Adherence with current GOLD guidelines is associated with 
lower healthcare utilization costs in subjects with moderate 
to severe COPD treated with LAMA plus LABA, LABA 
plus ICS or LAMA plus LABA/ICS therapies.
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